{
  "id": 5689044,
  "title": "Veracyte chief scientific & med officer sells over $564k stock",
  "url": "https://urgent.news/2026/09/05/veracyte-chief-scientific-med-officer-sells-over-564k-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-05T01:16:02.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/veracyte-chief-scientific--med-officer-sells-over-564k-stock-93CH-4890138"
  },
  "original_language": "en",
  "account": "Phillip G. Febbo, Veracyte's Chief Scientific and Medical Officer, sold 13,110 shares of the company's stock on September 4, 2026, for a total of $564,409. These sales were made in accordance with a pre-approved Rule 10b5-1 plan adopted by Mr. Febbo on August 21, 2025. The shares were sold at a weighted average price of $42.90 to $43.66 per share, as Veracyte's stock price was trading at $42.53, up 31% over the past year.\n\nDespite the sale, Mr. Febbo still holds a total of 133,048 shares of Veracyte common stock, following the withholding of 3,639 shares on September 2, 2026, to cover tax obligations related to the vesting of restricted stock units. This withholding transaction was separate from the stock sales and did not involve a reduction in his ownership stake.\n\nVeracyte recently reported strong second-quarter 2026 earnings, surpassing analysts' expectations with adjusted earnings of $0.54 per share and revenue of $150.3 million. The company has since raised its full-year revenue outlook, leading to supportive reactions from analysts such as Freedom Capital and Needham, who raised their price targets for the stock. However, Canaccord adjusted its price target downward, indicating varying opinions on the company's future revenue prospects.",
  "summary": null,
  "key_points": [
    "Phillip G. Febbo sold 13,110 Veracyte shares for $564,409 on Sep 4, 2026",
    "Sales made per Rule 10b5-1 plan adopted Aug 21, 2025",
    "Febbo still holds 133,048 Veracyte shares after tax withholding"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}